Glutamine Enhances Selectivity of Chemotherapy Through Changes in Glutathione Metabolism

  title={Glutamine Enhances Selectivity of Chemotherapy Through Changes in Glutathione Metabolism},
  author={K. A. Rouse and Emmanuel Nwokedi and Jeffrey E. Woodliff and John Epstein and Vicki Suzanne Klimberg},
  journal={Annals of Surgery},
ObjectiveChemotherapy doses are limited by toxicity to normal tissues. Intravenous glutamine protects liver cells from oxidant injury by increasing intracellular glutathione (GSH) content. The authors hypothesized that supplemental oral glutamine (GLN) would increase the therapeutic index of methotrexate (MTX) by improving host tolerance through changes in glutathione metabolism. The authors examined the effects of oral glutamine on tumor and host glutathione metabolism and response to… Expand
Effect of glutamine on methotrexate efficacy and toxicity.
These studies suggest that GLN supplementation is safe in its administration to the tumor-bearing host receiving MTX, and may serve to increase the therapeutic window of this chemotherapeutic age. Expand
Glutamine Affects Glutathione Recycling Enzymes in a DMBA-Induced Breast Cancer Model
The paradoxical effect of GLN on key GSH recycling enzymes in the gut versus tumor suggests that dietary supplemental GLN could be used in the clinical practice to increase the therapeutic index of cancer treatments by protecting normal tissues from, and sensitizing tumor cells to, chemotherapy and radiation-related injury. Expand
Glutamine supplementation in cancer patients.
Glutamine supplementation can attenuate loss of protein in the muscle in tumor-bearing animals and protect immune and gut-barrier function during radiochemotherapy in patients with advanced cancer. Expand
Glutamine protects against doxorubicin-induced cardiotoxicity.
Doxorubicin dose-intensive therapy for breast cancer is limited by a cardiomyopathy that often results in overt congestive heart failure, so data suggest that dietary GLN supplementation may diminish DOX-induced oxidative damage and thus cardiotoxicity through upregulation of cardiac GSH metabolism. Expand
Effects of glutamine supplements and radiochemotherapy on systemic immune and gut barrier function in patients with advanced esophageal cancer.
Oral glutamine supplementation protects lymphocytes and attenuates gut permeability in patients with esophageal cancer during radiochemotherapy. Expand
Effect of dietary glutamine on tumor glutathione levels and apoptosis-related proteins in DMBA-induced breast cancer of rats
The results have shown that GLN supplementation caused a significant decrease in the tumor GSH levels and the ratio GSH/oxidized GSH (GSSG), accompanied by up- regulation of Bax and caspase-3, and down-regulation of Bcl-2. Expand
Gut glutathione metabolism and changes with 7,12-DMBA and glutamine.
Oral GLN restores to normal GSH production in DMBA-treated animals suggesting one of the mechanism(s) by which GLN prevents breast cancer in this model is suggested. Expand
Bolus oral glutamine protects rats against CPT-11-induced diarrhea and differentially activates cytoprotective mechanisms in host intestine but not tumor.
The data demonstrate a striking dichotomy in the response of tumor and host to oral glutamine administration, concurring with the concept that this nutrient may favorably alter the balance between the host and tumor. Expand
Pre-treatment with glutamine reduces genetic damage due to cancer treatment with cisplatin.
Glutamine is able to prevent genotoxic and clastogenic damages caused by cisplatin, and this activity is evaluated in 40 Swiss mice. Expand
Dichotomic actions of glutamine in host versus tumour: an emerging concept
Recent studies have shown that GLN could have dichotomic actions in host versus in tumour, probably in link with glutathione metabolism, suggesting thatGLN could be used in clinical practice to increase the therapeutic index of oncological treatments. Expand